Evolving the Patient Experience

The newly released FDA approved Suboxone Film is indicated for maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. The prescription use is still limited under the Drug Addiction Treatment Act, however, this innovation helps address compliance challenges:

   Suboxone Sublingual Film Dissolve Time—Dissolves faster than the sublingual tablets presently in use.
            a). Suboxone Film dissolves completely under the tongue faster than the            
            Suboxone Tablet
            b). In clinical trials, Suboxone Film 8 mg dissolved nearly twice as fast as
            Suboxone Tablet 8 mg.

   Suboxone Sublingual Film Taste—Favorable taste rating
            a). In a patient questionnaire, more than 71% of patients who tried Suboxone
            Film rated the taste as neutral or better on a 10-point scale.

  
Portability—Compact unit-dose pouches
            a). Unit-dose, child resistant pouches are easy to carry
            b). Patients who carry Suboxone Film with them should be advised to also carry their pharmacy label

Discount Offer: Limited Time Only

A patient offer for up to $75 in out-of-pocket savings with the Suboxone Film savings program is available. Information regarding the offer is available at Winter Park Recovery Center.

Comparable Efficacy and Safety of Suboxone Film to Suboxone Tablet

Clinically the Suboxone Film is interchangeable with the Suboxone Tablet.

•         In a clinical study where patients were transferred to Suboxone Film at their Suboxone Tablet dose
a). The transfer from Suboxone Tablet to Suboxone Film was effective
b). The difference between formulations was not clinically significant
c). 1 out of 176 participants received a dose adjustment (increase) during the first 2 weeks of the trial
d). Safety trial results indicate that Suboxone Film is well tolerated and has a safety profile comparable to Suboxone Tablet

•    Reduces illicit opioid use and increases treatment retention by suppressing opioid withdrawal symptoms and reducing      
      cravings
•   Once daily dosing due to a long duration of effect, just as with Suboxone Tablet
•    A dose adjustment may be needed for patients switching from Suboxone Tablet to Suboxone
     Film due to potential individual variability in bioavailability
•    The most common adverse event (>1%) associated with the sublingual administration of the
      Suboxone Film was oral hypoesthesia. Other adverse events were constipation, glossodynia,
      oral erythema, vomiting, intoxication, disturbance in attention, palpitations, insomnia,
      withdrawal syndrome, hyperhidrosis and blurred vision.
•    Patients are able to transfer from Suboxone Tablet to Suboxone Film easily and effectively.

Suboxone Sublingual Film: Helping Address Public Health Needs

•    Child-resistant unit-dose packaging
            a). Pouches achieved a high level of child resistance
            b). Unit-dose packaging to reduce the risk of multi-dose exposure
•    Suboxone Film formulation discourages misuse and abuse
            a). Suboxone Film formulation makes it difficult to crush into a powder and snort
            b). Suboxone Film contains naloxone. If injected, noxalone attenuates the effects of buprenorphine and precipitates
            withdrawal in individuals dependent on full opioid agonists, but has no effect when taken sublingually
•    Protecting treatment through a Risk Evaluation and Mitigation Strategy  (REMS)
            a). REMS consists of a set of tactics designed to help promote the appropriate use of
            buprenorphine and help protect the in-office treatment of opioid dependence
•    Includes various materials and processes developed to assist in:
            a). Mitigating the risk of accidental overdose, misuse, and abuse
            b). Informing patients of the serious risks associated with buprenorphine